Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7861/clinmed.2020-0524 http://scihub22266oqcxt.onion/10.7861/clinmed.2020-0524 32863273!7687338!32863273     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Med+(Lond) 2020 ; 20 (6): e215-e217 Nephropedia Template TP {{tp|p=32863273|t=2020. Antiviral treatment for COVID-19: the evidence supporting remdesivir |pdf=|usr=}}{{32863273}} gab.com Text Antiviral treatment for COVID-19: the evidence supporting remdesivir JO: Clin Med (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=32863273 #FOAvip The emergence of the novel beta coronavirus SARS-CoV-2 and the ensuing COVID-19 pandemic has generated a rapidly evolving research landscape in the search for new therapeutic agents. The intravenous antiviral drug remdesivir has in vitro activity against SARS-CoV-2 and now studies have reported its clinical efficacy, demonstrating shorter time to recovery in hospitalised patients with severe COVID-19. Adverse event rates were low and remdesivir has now received conditional marketing authorisation from the European Medicines Agency. An interim clinical commissioning policy is in place in the UK. These studies make remdesivir the first antiviral drug able to alter the natural history of severe COVID-19, and a benchmark for the comparison of new therapies in the future. Ongoing studies are investigating its use in early mild/moderate COVID-19, alternative formulations, and the combination of remdesivir with immunomodulatory agents. Twit Text FOAVip Antiviral treatment for COVID-19: the evidence supporting remdesivir ????Clin Med (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=32863273 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32863273 #FOAvip English Wikipedia <ref>{{Cite pmid|32863273}}</ref> Antiviral treatment for COVID-19: the evidence supporting remdesivir #MMPMID32863273 Richardson C; Bhagani S; Pollara G Clin Med (Lond) 2020[Nov]; 20 (6): e215-e217 PMID32863273show ga The emergence of the novel beta coronavirus SARS-CoV-2 and the ensuing COVID-19 pandemic has generated a rapidly evolving research landscape in the search for new therapeutic agents. The intravenous antiviral drug remdesivir has in vitro activity against SARS-CoV-2 and now studies have reported its clinical efficacy, demonstrating shorter time to recovery in hospitalised patients with severe COVID-19. Adverse event rates were low and remdesivir has now received conditional marketing authorisation from the European Medicines Agency. An interim clinical commissioning policy is in place in the UK. These studies make remdesivir the first antiviral drug able to alter the natural history of severe COVID-19, and a benchmark for the comparison of new therapies in the future. Ongoing studies are investigating its use in early mild/moderate COVID-19, alternative formulations, and the combination of remdesivir with immunomodulatory agents. |*Antiviral Agents/administration & dosage/adverse effects/therapeutic use[MESH] |Adenosine Monophosphate/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use[MESH] |Administration, Intravenous[MESH] |Alanine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |Randomized Controlled Trials as Topic[MESH]Antiviral treatment for COVID-19: the evidence supporting remdesivir (epmc).pdf DeepDyve Pubget Overpricing